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Abstract 
The EGFR gene and ALK rearrangements are two genetic drivers of non-small cell lung cancer (NSCLC). The frequency 
of EGFR mutations and ALK rearrangement varies according to not only ethnicity but also gender, smoking status 
and the histological type of NSCLC. In the present study, we demonstrated the distribution of EGFR mutations in 
132 NSCLC patients by using a pyrosequencing technique and the distribution of ALK rearrangements in 51 NSCLC 
patients by using fluorescent in situ hybridization technique in Turkey. Additionally, we compared the clinicopatho-
logical data of NSCLC patients with the mutation status of EGFR in their cancerous tissues. Both EGFR mutations and 
ALK rearrangements were identified in 19 (14.39 %) and 1 (1.96 %) patients, respectively. We found EGFR mutations in 
codon 861, 719 and 858 with the ratios of 10.52 % (2/19), 10.52 % (2/19) and 31.58 % (6/19), respectively, and dele-
tion of exon 19 in 47.37 % (9/19) of the patients. We found the frequency of EGFR mutations to be significantly higher 
in female patients and nonsmokers (p = 0.043, p = 0.027, respectively). Consequently, we found EGFR mutations to 
be more frequent in female patients and nonsmokers. Future studies on larger patient groups would provide more 
accurate data to exhibit the relationship between EGFR mutations and ALK rearrangements and the clinicopathologi-
cal status.
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Background
Lung cancer is the most common cause of cancer-related 
deaths in males and females worldwide (Jemal et  al. 
2010). Non-small cell lung cancer (NSCLC) accounts 
for 80–85  % of all lung cancers. Most of the patients 
have advanced stages or metastatic disease (D’Addario 
et  al. 2010; Crinò et  al. 2010). A recent improvement 
in comprehending the molecular basis of the disease, 
especially NSCLC, has led to improvements in treat-
ment (Mok et  al. 2009). In recent years, because of the 
development of biomarker-driven personalized therapy, 
the treatment approach for many cancers including the 
NSCLC has changed (Vagulienė et  al. 2012). Various 
phase 3 trials have demonstrated the clinical efficacy of 
EGFR tyrosine kinase inhibitors (gefitinib and erlotinib) 
as first-line therapies compared with chemotherapy in 
advanced stage NSCLC patients with harboring activat-
ing EGFR mutations. Some clinical practice guidelines 
suggest testing EGFR mutation status before initiating 
the first-line treatment to patients with advanced stage 
NSCLC (Shi et  al. 2014). The EGFR gene is localized 
on the short arm of chromosome 7 and encodes a 170-
kDa type I transmembrane growth factor receptor. The 
EGFR receptor belongs to the HER/erbB family of tyros-
ine kinase. This receptor has an extracellular cysteine-
rich ligand-binding domain and an intracellular domain 
which has intrinsic tyrosine kinase activity. Intracellular 
signaling is mediated mainly by the RAS–RAF–MEK–
MAPK pathway, PI3K–PTEN–AKT pathway and the 
signal transducer and activator of transcription (STAT) 
pathways (De Luca et  al. 2008). These EGFR signaling 
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pathways are important for tumor cell growth, local inva-
sion, angiogenesis, protein translation,  autophagy and 
cell metabolism (Jimeno and Hidalgo 2006). Echinoderm 
microtubule-associated protein-like 4 and the anaplastic 
lymphoma kinase (EML4–ALK) fusion genes were iden-
tified in a subset of NSCLCs in 2007 (Soda et al. 2007). 
This fusion occurs due to chromosomal inversion or the 
translocation of chromosome 2 p and results in the for-
mation of EML4–ALK fusion gene.
The EML4–ALK translocation results in constitu-
tive ALK kinase activity and represents the oncogenic 
addiction pathway in NSCLC (Soda et  al. 2007, 2008). 
The ALK rearrangements that are found in up to 5 % of 
patients with NSCLC are related to younger age, no his-
tory of smoking and distinct clinicopathological features 
such as adenocarcinoma histology (Shaw et al. 2009; Sol-
omon et al. 2009; Tiseo et al. 2011; Wong et al. 2009). Cri-
zotinib, a targeted ALK tyrosine kinase inhibitor (TKI), 
is a promising agent in treating ALK-positive NSCLC 
patients and provides survival benefit (Kwak et al. 2010). 
It was approved by the US Food and Drug Administra-
tion (FDA) for treating advanced stage ALK-positive lung 
cancer.
The aim of the study was to examine the prevalence 
of EGFR-activating mutations and ALK rearrangements 
among patients with NSCLC and to evaluate the associa-
tions between EGFR mutations and clinicopathological 
characteristics.
Methods
One hundred and thirty two patients applying to 
Uludağ University Faculty of Medicine, Medical Genet-
ics Department for EGFR mutation analysis and 51 
patients applying for ALK translocation analysis with 
histopathologically proven NSCLC were enrolled in 
this retrospective study. The demographic (age, gender) 
and clinicopathological characteristics of the patients 
(smoking status, histological type and metastatic status) 
were compared with the results of molecular analysis. 
Approval for the study was granted by the local ethics 
committee.
EGFR mutation analysis using pyrosequencing
Formalin-fixed paraffin embedded tissue samples were 
obtained by tumor biopsy. The slides were examined 
by pathologists to confirm that they contain more than 
50  % of tumoral tissue, and they are appropriate for 
DNA extraction. The QIAamp® DNA FFPE tissue kits 
were used to extract the human DNA from formalin-
fixed paraffin-embedded tissue specimens (QIAGEN® 
kit, Germany). Single-stranded DNA was prepared, and 
the corresponding sequencing primers were annealed 
to the DNA. Therascreen EGFR Pyro Kit can detect and 
measure the mutations in human EGFR gene 719, 768, 
790, and 858–861 codons quantitatively and also detect 
the deletions and complex mutations in exon 19. The kit 
includes 4 PCR assays: one for detecting the mutations in 
codon 719 (exon 18), one for 768 and 790 (exon 20), one 
for codons 858–861 (exon 21) and one for the deletions 
in exon 19. Four regions were amplified separately and 
sequenced through the defined region. After using prim-
ers targeting 18, 19, 20 and 21, amplicons were immo-
bilized on Streptavidin Sepharose High Performance 
beads. The samples were analyzed in a PyroMark Q24 
system using Assay setup files and a run setup file. The 
unmethylated control DNA was included in the study 
as a positive control for the PCR and sequence analyses. 
Additionally, negative controls (without template DNA) 
were included per each PCR set up for at least one assay.
Fluorescent in situ hybridization (FISH) for EML4–ALK 
fusion
Formalin-fixed, paraffin-embedded tissue sections were 
localized on slides. The DNA was denatured to a single-
stranded form and was hybridized with DNA probes. 
Following the hybridization, the undyed probes were 
removed by a washing series, and the nuclei were coun-
ter-stained with DAPI (4,6 diamidino-2-phenylindole) 
(a DNA-specific stain that fluoresces blue). The hybridi-
zation of ALK probe (Vysis LSI ALK Dual Color, break-
apart rearrangement probe; Abbott Molecular, Abbott 
Park, IL) was examined using a fluorescence microscope 
equipped with appropriate excitation and emission fil-
ters, allowing the visualization of the orange and green 
fluorescent signals. If 2p23 ALK region is hybridized with 
Vysis ALK Break Apart FISH Probes, it appears as two 
adjacent or fused (overlapping) orange/green (yellow) 
signals in a natural position. However, if a chromosome 
rearrangement at the 2p23 ALK breakpoint region has 
occurred, one orange and one green signal separated by 
at least two signal diameters will be visualized. Alterna-
tively, a single orange signal (deletion of green signal) in 
addition to a fused or broken apart signal may be seen. If 
more than 100 tumor cells are counted, if >15 % of tumor 
cells showed a split red and green and/or single red pat-
tern, then the occurrence of an ALK gene rearrange-
ment is considered; otherwise, the specimen is classified 
as ALK FISH negative. The ALK positivity pattern (split, 
single red or both) was recorded.
Statistical analysis
The age variable was presented with median value (mini-
mum–maximum), and the other categorical variables 
of the study were presented in numbers and percent-
ages. The Pearson’s Chi square and Fisher’s exact Chi 
square tests were used for the comparisons of categorical 
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variables between mutation groups. Analyses were per-
formed with SPSS 22.0 (Chicago, IL) program, and 
p < 0.05 was considered statistically significant.
Results
The median age of 132 patients with NSCLC diagno-
sis was 60 (31–83) years. The demographic and clinico-
pathological characteristics of the patients are given 
in Table  1. EGFR mutation and ALK rearrangements 
were detected in 14.39  % (19/132) and 1.96  % (1/51) of 
the patients, respectively. We found EGFR mutations in 
codon 861, 719, and 858 in the following ratios: 10.52 % 
(2/19), 10.52  % (2/19) and 31.58  % (6/19) and detected 
exon 19 deletion in 47.37 % of the patients (9/19). Among 
all mutations, we found exon 19 deletions delE746-A750 
and delL747-p753, InsS with ratios of 42.11 % (8/19) and 
5.26  % (1/19), respectively. In one patient with codon 
719 mutation, we also detected a mutation at codon 
790. The comparison of clinicopathological characteris-
tics of EGFR mutation carriers and wild type patients is 
presented in Table 1. The patients were classified as ade-
nocarcinoma and the others (squamous, giant cell, aden-
osquamous) in terms of histological type.
EGFR mutation rates were higher in females than males 
(p  =  0.043) and higher in non-smokers than smokers 
(p = 0.027). We did not find additional significant asso-
ciations between EGFR mutation and patients’ clinico-
pathological characteristics (Table 1). Clinicopathological 
characteristics of a 54  year old female patient who had 
ALK rearrangements and EGFR wild type was smoker, 
adenocarcinoma histology and presence of metastasis.
Discussion
The molecular basis of lung cancer is complex and het-
erogeneous. The molecular changes in multiple levels 
(genetic, epigenetic, protein expression) and the improve-
ments in the comprehension of the functional expres-
siveness of these changes have potential effects for the 
diagnosis, prognostication and treatment of lung cancer. 
EGFR mutations are related to the pathogenesis of many 
types of cancers including NSCLC (Cooper et  al. 2013). 
Activating mutations of the EGFR gene were reported in 
10–15 % of unselected Western patients (Yip et al. 2013; 
Shigematsu et al. 2005; Eberhard et al. 2008; Russell et al. 
2013) and 30–40  % of Asian populations (Kosaka et  al. 
2004; Tokumo et  al. 2005; Yoshida et  al. 2007). EGFR 
mutations in NSCLC are seen in the first 4 exons of intra-
cellular tyrosine kinase domain. They are most commonly 
frame deletions of exon 19 (~45 %) and have over 20 vari-
ants, and the most common of which is delE746-A750. 
The next most common mutations are missense muta-
tions, particularly L858R in exon 21, a single nucleotide 
point mutation leading to a single amino acid change 
from leucine to arginine at codon 858 (~40  %). How-
ever, Yip et  al. reported that 14  % of the EGFR muta-
tions of patients with early stage lung cancers comprised 
Table 1 The demographic and clinicopathological characteristics of the patients and the comparison of clinicopathologi-
cal characteristics of EGFR mutation carriers and wild type patients
EGFR epidermal growth factor receptor
* p value were derived from a comparison between never and ever smoking status
Characteristics All patients (n = 132) Patients with EGFR  
mutation (n = 19)





<65 91 (68.9 %) 12 (13.2 %) 79 (86.8 %)
≥65 41 (31.1 %) 7 (17.1 %) 34 (82.9 %)
Gender 0.043
Male 98 (74.2 %) 10 (10.2 %) 88 (89.8 %)
Female 34 (25.8 %) 9 (26.5 %) 25 (73.5 %)
Smoking status 0.027*
Never 60 (45.5 %) 13 (21.7 %) 47 (78.3 %)
Ever 56 (42.4 %) 4 (7.1 %) 52 (92.9 %)
Unknown 16 (12.1 %) 2 (12.5 %) 14 (87.5 %)
Histology 0.546
Adenocarcinoma 127 (96.2 %) 18 (14.2 %) 109 (85.8 %)
Others 5 (3.8 %) 1 (20 %) 4 (80 %)
Metastasis status 0.780
Present 98 (74.2 %) 15 (15.3 %) 83 (84.7 %)
Absent 34 (25.8 %) 4 (11.8 %) 30 (88.2 %)
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activating mutations of exon 18 and that L858R mutations 
accounted for only 29 % of EGFR mutations in an Austral-
ian population (Yip et al. 2013). Additionally, there are less 
common types of mutations including the frame duplica-
tions and insertions in exon 20 (~5–10 %), most of which 
are related to EGFR-TKI resistance (Tam et  al. 2006; 
Yamamoto et al. 2009). Doğan et al. reported that all of the 
EGFR mutations they detected in 7.4 % of 42 patients with 
advanced stage NSCLC were exon 19 deletions (Dogan 
et  al. 2014). Shigematsu and Gazdar (2005), one of two 
major series (Shigematsu and Gazdar 2005; Murray et al. 
2008) on epidemiology of EGFR mutations stated that all 
the reported mutations were somatic mutations at exon 
18–21 of EGFR gene encoding a part of intracellular TK 
domain. Three different mutation types related to EGFR-
TKIs sensitivity were defined: (1) in-frame deletions at 
exon 19 which are the most common mutations account-
ing for 46 % of EGFR mutations, (2) missense mutations at 
exon 18, 20 or 21 (primarily the single-nucleotide substi-
tutions, L858R at exon 21) that are the second most com-
mon mutations accounting for 41  % of EGFR mutations 
and (3) in-frame duplications/insertions at exon 20 that 
constitute 5  % of all EGFR mutations. It was found that 
EGFR mutations are associated with EGFR-TKIs sensitiv-
ity as well as East Asian ethnicity, female gender, no his-
tory of smoking and adenocarcinoma histology.
Murray et  al. (2008) screened the data of 12,244 
patients and noted 3381 EGFR mutations. Exon 19 muta-
tions were the most common (50 %) followed by exon 21 
(40 %), 20 (6 %), and 18 mutations (4 %). Whereas L858R 
and delE746-A750 constituted 32.8 and 24.3  %, respec-
tively, 50  % of the mutations were deletions of exon 19 
or deletion-insertions. There was a significant relation-
ship between TKI response and presence of mutation, 
and although exon 19 mutations have the best response 
rates (70  %), exons 21, 18 and 20 have a response rate 
of approximately 20 % or slightly more (Shigematsu and 
Gazdar 2005; Murray et al. 2008). Ünal et al. found EGFR 
mutations in 42.6 % of 48 patients with NSCLC in their 
study in Western Turkey in which 9 of the mutations 
were at exon 20; 7 were at exon 19 and 2 were at exon 
21 (Unal et  al. 2013). In the present study, we detected 
EGFR mutations in 14.39 % (19/132) of NSCLC patients, 
and the mutations were in codons 861, 719 and 858 with 
the following rates: 10.52  % (2/19), 10.52  % (2/19) and 
31.58 % (6/19), respectively, and deletion of exon 19 was 
seen in a ratio of 47.37 % (9/19). delE746-A750 accounted 
for 42.11 % of all mutations, and it was the most common 
mutation. Our results were consistent with the literature.
The data from the literature indicate that the muta-
tions are more frequent in females compared with males 
(42 vs. 14  %), in non-smokers compared with smok-
ers (51 vs. 10  %) and in patients with tumor histology 
of adenocarcinoma compared with other types (40 vs. 
3 %) (Jimeno and Hidalgo 2006; Paez et al. 2004; Lynch 
et al. 2004; Pao et al. 2004; Shigematsu and Gazdar 2006; 
Mitsudomi et al. 2006; Jänne et al. 2004; Sakurada et al. 
2006). Additionally, Vaguliene et  al. found that EGFR 
mutations were significantly more frequent in females 
and nonsmokers in a study of 103 patients with NSCLC 
(Vagulienė et al. 2012). Ünal et al. found that EGFR muta-
tions were significantly more frequent in non-smoking 
NSCLC patients in Western Turkey (Unal et al. 2013). In 
contrast to majority of published data, Skov et al. (2015) 
and Hsiao et  al. (2014) found no difference in mutation 
rate among men and women. In our study, we found that 
EGFR mutations were more common in females and 
non-smokers.
In former studies, ALK rearrangement frequency was 
reported to be 3–13 % using FISH technique in NSCLC 
patients (Shaw et al. 2009; Inamura et al. 2008; Lin et al. 
2009). In those studies, it was stated that ALK rearrange-
ments were more common in nonsmoking patients, 
younger patients and adenocarcinoma histology and that 
it rarely coincided with the presence of an EGFR muta-
tion (Shaw et al. 2009; Wong et al. 2009; Takahashi et al. 
2010). Wang et al. detected ALK rearrangements in 9.6 % 
(32/332) of 332 patients with primary lung adenocarci-
noma (Wang et al. 2014). In the present study, we found 
ALK rearrangement in 1.96  % (1/51) of our patients; 
however, we could not establish an association with clin-
icopathological parameters due to a limited number of 
patients with ALK rearrangements.
A few weaknesses of the study should be mentioned. 
First, this is a single center study. Second, our study 
was performed on a relatively small population. Finally, 
although the cohort is complete and genetically homog-
enous, the mutation rate is dependent on the prevalence 
of smoking.
Conclusions
We detected EGFR mutation and ALK rearrangements at 
proportions of 14.39 and 1.96 %, respectively. We found 
that EGFR mutations were significantly more common in 
females and nonsmokers. The distinctness in prevalence 
reported in various studies may be related to differences 
in patient populations and may also stem from the diver-
sity in sensitivity of the techniques to analyze mutations. 
Further studies in larger patient groups would provide 
more accurate information to exhibit the association 
between clinicopathological characteristics and EGFR 
mutations and ALK rearrangements.
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